Announcement • May 22
Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026 Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., China Announcement • Apr 30
Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting Policies The board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval. Announcement • Apr 29
Pharmaron Beijing Co., Ltd. Announces Board Resignations Pharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service. Announcement • Mar 31
Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Announcement • Jan 22
Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.
Security Name: H shares
Security Type: Common Stock
Securities Offered: 58,440,762
Price\Range: HKD 22.82
Transaction Features: Subsequent Direct Listing Announcement • Jan 15
Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.
Security Name: H shares
Security Type: Common Stock
Securities Offered: 58,440,762
Price\Range: HKD 22.82
Transaction Features: Subsequent Direct Listing Announcement • Jan 14
Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025 Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567. Announcement • Dec 31
Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026 Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026 Announcement • Oct 29
Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. on October 28, 2025. With this transaction, it will further enhance its service capabilities in protein science, biological assaying and compound screening, protein crystallization and structure analysis and structure-based drug design.
The transaction is expected to close upon the satisfaction of customary closing conditions. Announcement • Sep 30
Pharmaron Beijing Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Announcement • Jul 02
Pharmaron Beijing Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025 Pharmaron Beijing Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 Announcement • Jun 20
Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025 Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025. Announcement • May 29
Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025 Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025, at 13:30 China Standard Time. Location: no. 1 meeting room,4th floor, grand skylight international hotel beijing, building 10, avic plaza, no. 15 ronghua south road, yizhuang economic and technological development, zone, daxing China Announcement • Apr 28
Pharmaron Beijing Co., Ltd. Announces Resignation of Hu Baifeng as Non-Executive Director and A Member of the Strategy Committee Pharmaron Beijing Co., Ltd. announced that Mr. Hu Baifeng (Mr. Hu) has tendered a voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board (the Strategy Committee). Following Mr. Hu's resignation, he has voluntarily agreed to continue to perform his duties as a non-executive Director and a member of the Strategy Committee until the proposed election of the new non-executive Director is resolved by the shareholders of the Company (the Shareholders) at the upcoming annual general meeting of the Company for the year 2024 (the 2024 AGM). Announcement • Mar 31
Pharmaron Beijing Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025 Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025 Announcement • Mar 26
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024 Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024. Announcement • Dec 31
Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2024 Results on Mar 27, 2025 Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2024 results on Mar 27, 2025 Announcement • Sep 30
Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Announcement • Jun 29
Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Pharmaron Beijing Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • Jun 22
Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million. Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million and with potential for an additional milestone payment. on May 16, 2024. The transaction is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close mid-year 2024. Centerview Partners LLC served as exclusive financial advisor, and Goodwin Procter as legal counsel to Proteologix on the transaction. The transaction has been approved by Pharmaron Beijing Co., Ltd's board.As of year ended 2023, Proteologix, Inc reported total assets of $31.04 million, total common equity of $30.73 million, EBIT of $5.74 million and net income of $5.74 million. Janet Xiao of Morrison & Foerster LLP acted as legal advisor to Proteologix, Inc.Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders on June 21, 2024. Announcement • Jun 21
Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024 Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024. Announcement • Jun 08
Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024 Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024. Announcement • May 16
Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024 Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024, at 13:30 China Standard Time. Location: paris hall, 3/f, pullman beijing south, no. 12 ronghua south road, beijing economic and technological development, area, daxing district, beijing China Announcement • Mar 30
Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Mar 27
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023 Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Announcement • Jan 29
Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023 Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229. Announcement • Dec 29
Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024 Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024